Cancer surgery avoidance study withdrawn before it began

NCT ID NCT06410534

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study aimed to see if the immunotherapy drugs nivolumab and ipilimumab could help people with colorectal or gastroesophageal cancer avoid or delay major surgery. It was designed for adults with stage I to III cancers. However, the trial was withdrawn by the sponsor before enrolling any participants, so no data were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

nivolumab and ipilimumab

What this could lead to

If this approach had worked, it could have pointed toward a way for some patients to avoid major surgery and preserve their organs.

What could go wrong

The study was withdrawn before any participants were enrolled, so no results are available. It is unknown whether the combination would have been effective or safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm gastroesophageal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States